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Summary
von Hippel-Lindau disease (VHL [MIM 193300]) is a
heritable autosomal dominant multiple-neoplastic dis-
order with high penetrance. It is characterized by brain
and spinal-cord hemangioblastomas, retinal angiomas,
clear-cell renal carcinoma, neuroendocrine tumors and
cysts of the pancreas, pheochromocytomas, endolym-
phatic-sac tumors, and papillary cystadenomas of the
epididymis and broad ligament. Although most index
cases have a positive family history of VHL, some do
not and may represent de novo cases. Cases without a
family history of VHL may or may not have a germline
mutation in their VHL tumor-suppressor gene. We pre-
sent two cases of VHL mosaicism. In each of two fam-
ilies, standard testing methods (Southern blot analysis
and direct sequencing) identified the germline mutation
in the VHL gene of the offspring, but not in their clin-
ically affected parent. Additional methods of analysis of
the affected parents’ blood detected the VHL-gene mu-
tation in a portion of their peripheral blood lympho-
cytes. In one case, detection of the deleted allele was by
FISH, and, in the second case, the 3-bp deletion was
detected by conformational sensitive gel electrophoresis
and DNA sequencing of cloned genomic DNA. Mosa-
icism in VHL is important to search for and recognize
when an individual without a family history of VHL has
VHL. Patients diagnosed without family histories of the
disease have been reported in as many as 23% of kin-
dreds with VHL. Identification of individuals potentially
mosaic for VHL will affect counseling of families, and
these individuals should themselves be included in clin-
ical screening programs for occult disease.
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Introduction
von Hippel-Lindau disease (VHL [MIM 193300]) is a
rare, heritable, autosomal dominant disorder character-
ized by a predisposition to develop benign andmalignant
tumors in multiple organ systems (Glenn et al. 1990;
Choyke et al. 1995). Individuals at risk may develop
tumors of the CNS (hemangioblastomas), eye (retinal
angiomas), kidneys (clear-cell renal-cell carcinoma
[RCC]), adrenal glands (pheochromocytoma), pancreas
(cysts and neuroendocrine tumors), inner ear (endolym-
phatic sac tumors) (Manski et al. 1997), and broad lig-
ament and epididymis (papillary cystadenomas)
(Choyke et al. 1997). The incidence of VHL ranges from
1 in 36,000 to 1 in 45,500 (Maher et al. 1991; Neumann
and Wiestler 1991; Maddock et al. 1996) live births in
white populations. Although there is nearly complete
penetrance by age 65 years (Maher et al. 1991), there
are exceptions. Estimated mutation rates range from 1.4
# 106 to 4.4# 106 per gene per generation (Maddock
et al. 1996). The proportion of cases caused by new
mutations is unknown.
Phenotypes vary among families (Glenn et al. 1991;
Neumann and Bender 1998), and a VHL classification
system based on observed phenotype differences has
been proposed (Chen et al. 1995; Choyke et al. 1995).
This schema divides VHL into type I (without pheo-
chromocytoma) and type II (with pheochromocytoma),
with subcategories IIA (VHL without predisposition to
clear-cell RCC) and IIB (VHL with predisposition to
clear-cell RCC). These differences in phenotype reflect
differences in genotype (Zbar et al. 1996; Stolle et al.
1998).
In 1988 the VHL gene was mapped to chromosome
3 (Seizinger et al. 1988) and was isolated by positional
cloning in 1993 (Latif et al. 1993). The detection of
germline mutations in families has recently been reported
to be 100% (Stolle et al. 1998) on the basis of both
qualitative and quantitative Southern blotting and
DNA-sequence analysis. Most index cases who test pos-
itive for a VHL mutation have a positive family history
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Table 1
Phenotypic Characteristics of Parents with VHL Mosaicism and Affected Offspring
FAMILY 1 FAMILY 2
Index Case Mosaic Parent Index Case Mosaic Parent
Sex Female Female Female Male
No. of siblings 0 ) 5 )
VHL diseasea PC, CNS PC, CNS, KC CNS, K, RA, PC CNS, PC, KC, RCC
a CNS = central nervous system hemangioblastomas; K = solid kidney lesion detected by
CT scan; KC = renal cysts (simple renal cysts alone are not diagnostic of VHL); PC =
pancreatic cysts; RCC = renal-cell carcinoma; and RA = retinal angioma.
of VHL disease; however, some individuals report no
history of VHL in either parental lineage. Among 181
kindreds with VHL that were evaluated by the National
Institutes of Health (NIH), 42 (23%) appeared, by fam-
ily history, to be first-generation diagnoses (Glenn et al.
1999). First-generation diagnoses may result from a new
mutation occurring during oogenesis or spermatogenesis
in the parent. Another possibility is that the seemingly
unaffected parent is mosaic for the disease because of a
somatic mutation acquired during early development.
Mosaicism is defined as the presence in an individual
of at least two cell lines differing in genotype and arising
from a single zygote (Austin and Hall 1992). Depending
on the stage of development and the cell in which the
mutation occurred, the individual may be unaffected or
may have clinical disease (Zlotogora 1998; Kent-First
1999). The finding of mosaicism has important impli-
cations both in counseling family members and in risk
assessment for disease development in the individual
with VHL mosaicism (Zlotogora 1998).
We report two detected cases of mosaicism in VHL,
one in a male patient and one in a female patient. Both
patients had clinical VHL disease but were negative for
VHL mutations, according to testing of their peripheral
blood lymphocytes (PBLs) by standard methods. Each
had an offspring with known clinical VHL disease, and
both offspring had a documented germline mutation in
the VHL tumor-suppressor gene. We believe this to be
the first report of mosaicism in individuals with VHL
disease.
Subjects and Methods
Clinical Evaluation
Two families, each with index cases affected by VHL
disease, were identified from the NIH-VHL Family Reg-
istry of patients screened under a National Cancer In-
stitute (NCI) review board–approved protocol. The bi-
ological parents of each index case were alive and eligible
for testing. In both kindreds, there was no parental his-
tory of VHL at the time of diagnosis of the index case.
Subjects were counseled, and informed consent was ob-
tained. Affection status was determined by medical ex-
aminations, conducted at the NIHClinical Center,which
included physical examinations, radiological evalua-
tions, and laboratory testing according to methods de-
scribed elsewhere (Choyke et al. 1995; Manski et al.
1997).
Mutation Analysis
Southern blot analysis and DNA-sequence analysis
was performed according to methods described else-
where (Stolle et al. 1998). FISH analysis was carried out
on B-cell lymphocytes (Pack et al. 1999). Conforma-
tional sensitive gel electrophoresis (CSGE) was per-
formed on amplified genomic or plasmid DNA, as de-
scribed by Ganguly et al. (1993). PCR products of
genomic DNA were cloned into a TA cloning vector
(Clonetech) according to the manufacturer’s instruc-
tions. Insert DNA was amplified directly from crude lys-
ates of bacterial colonies and was mixed with the PCR
product from control DNA and then was screened for
mutations by CSGE and DNA sequencing. DNA was
extracted from buccal swabs (Richards et al. 1993) and
was amplified for 35 cycles with primers for exon 1
(Stolle et al. 1998). A 2-ml aliquot of this reaction was
then reamplified for an additional 25 cycles prior to
analysis.
Results
Details of clinical characteristics and mutations in the
VHL gene in the affected offspring and mosaic parents
are shown in tables 1 and 2. In family 1 (fig. 1), VHL
was initially diagnosed in the daughter (III:1) at age 24
years, when she was found to have CNS hemangiob-
lastomas. Subsequent evaluation by computed tomog-
raphy (CT) of the abdomen revealed pancreatic cysts
(fig. 2A). DNA analysis of this individual (III:1) by quan-
titative Southern blot revealed a deletion of one entire
allele of the VHL gene (fig. 3, lane 3). Direct sequencing
of the other allele revealed only normal sequence. Both
parents of III:1 subsequently underwent full clinical eval-
uation at the NIH. Clinical evaluation of the mother
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Figure 1 Pedigrees of families 1 (top) and 2 (bottom), which have VHL with parental mosaicism. Arrows indicate probands. Blackened
circles and squares indicate individuals with VHL disease. For keys to disease codes, see table 1.
(II:2) revealed findings consistent with very mild VHL
disease (2-mm enhancing nodule in the cerebellum, con-
sistent with hemangioblastoma; several pancreatic cysts
[fig. 2B]; and a solitary left-renal cyst). Quantitative
Southern blot analysis of DNA extracted from PBLs of
II:2 did not detect the mutation found in III:1 (fig. 3,
lane 4). FISH analysis revealed the deletion of one allele
of the VHL gene in 47% of 50 metaphases scored (Pack
et al. 1999). Individual III:1 had no siblings.
In family 2 (fig. 1), the affected daughter (IV:6) was
diagnosed with VHL disease at age 15 years, when she
developed symptoms caused by spinal cord hemangiob-
lastomas (fig. 2C). At age 20 years, she was diagnosed
with multiple cystic lesions in the right kidney, a solid
lesion of the left kidney, multiple pancreatic cysts, and
a small peripheral retinal angioma. Approximately 1
year after IV:6 was diagnosed with VHL, her father (III:
4) developed hematuria. Evaluation and subsequent
treatment confirmed disease consistent with VHL, in-
cluding clear-cell renal-cell carcinoma, renal cysts, pan-
creatic cysts, and multiple hemangioblastomas of the
cerebellum and lower brainstem (fig. 2D). Southern blot
analysis and DNA sequencing of the VHL gene in the
father’s PBLs were negative (fig. 4A) by the initial genetic
testing, on the basis of standard methods that identified
VHL mutations in 99 of 99 (Stolle et al. 1998) and in
a subsequent total of 131 of 131 (Glenn et al. 1999)
affected individuals. However, genetic testing of the
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Figure 2 Radiographic images for mosaic parents and affected offspring. A, 27-year-old woman with VHL, from family 1 (individual III:
1). Computed tomography of the abdomen demonstrates multiple cysts in the pancreas (arrows). B, 49-year-old woman, with mosaicism for
VHL, from family 1 (individual II:2). Computed tomography of the abdomen demonstrates milder cystic changes within the pancreas. C, 23-
year-old woman, with VHL, from family 2 (individual IV:6). Magnetic resonance imaging of the spine with gadolinium enhancementdemonstrates
hemangioblastoma (arrow) in the low brainstem and a tiny additional hemangioblastoma at C2-3 (curved arrow). D, 48-year-old man, with
VHL mosaicism, from family 2 (individual III:4) demonstrates hemangioblastomas (arrows) at the same site (as IV:6) in the low brainstem and
an additional lesion in the cerebellum. Additional sections (not shown) showed multiple cerebellar hemangioblastomas.
daughter’s (IV:6) PBLs by direct sequencing revealed a
3-bp deletion (TTC) at nucleotides 439–441 (fig. 4B).
After identification of the mutation in IV:6, the father’s
DNA was again analyzed, by application of additional
methods directed specifically at the region of the 3-bp
deletion. By use of CSGE, a faint shifted band was ob-
tained with the PCR product from exon 1 (fig. 5, lane
3), suggesting the presence of at least some mutant mol-
ecules. This PCR product was cloned into a TA cloning
vector and was used to transform competent bacteria.
Insert DNA was amplified directly from bacterial lysates
of individual colonies and was subjected to analysis by
CSGE. Of the 52 colonies evaluated, 4 exhibited a gel
shift. DNA-sequence analysis confirmed the presence of
the delTTC mutation (fig. 4C). These results suggest that
the father is mosaic for the mutation identified in his
daughter and that the mutation was present in approx-
imately one of seven PBLs.
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Figure 3 Quantitative Southern blot analysis, family 1. Southern
blots of EcoRI- and AseI-digested genomic DNA were hybridized to
probes specific for the VHL gene (g7) (Latif et al. 1993) and the human
beta-globin gene (Stolle et al. 1987). With equal loading of DNA, as
assessed by the intensity of the beta-globin gene band, complete de-
letion of the VHL gene is apparent from the decreased intensity of the
VHL gene band in patient samples, relative to that in unaffected con-
trols. Samples with a partial deletion of the VHL gene exhibit an
abnormally migrating band. Lanes 1, 2, and 7, Control DNA. Lane
3, DNA from III:1. Lane 4, DNA from II:2. Lanes 5 and 6, DNA from
patients with complete or partial deletions of the VHL gene,
respectively.
Figure 4 DNA-sequence analysis, family 2. A portion of the
VHL gene containing exon 1 sequence was amplified as described
elsewhere (Stolle et al. 1998) from either genomic DNA or plasmid
DNA containing a cloned DNA insert and was subjected to DNA-
sequence analysis. A, Sequence of genomic DNA from III:4. B, Se-
quence of genomic DNA from IV:6. C, Sequence of cloned DNA from
III:4. Note that the sequence in B indicates that this patient is hetero-
zygous for a frameshift mutation. The sequence of the cloned DNA
in C reveals that the frameshift is due to a 3-bp (TTC) deletion in this
region.
To determine the extent of mosaicism in the father
(III:4), additional samples of DNA were obtained from
buccal epithelial cells and cultured skin fibroblasts. The
presence of the mutation in these tissues was detected
by the appearance of faint bands on CSGE analysis of
amplified DNA from buccal cells or cultured skin fibro-
blasts (fig. 5, lanes 4 and 5). These results support the
conclusion that this individual is mosaic for a VHL
mutation.
There were five other children (siblings of IV:6) in this
family. One (IV:7) underwent clinical screening at the
NIH and showed no evidence of VHL and was later
shown to be negative for the 3-bp VHL deletion. The
four remaining siblings have not been evaluated at the
NIH; however, two siblings tested negative for the VHL
mutation, by DNA-sequence analysis.
Discussion
Postzygotic mutations result in mosaicism. It is im-
portant to recognize that mosaicism is a potential cause
for failure of molecular diagnosis in VHL and may man-
ifest as a single-system disease or as a multisystem dis-
ease. Mosaicism has been described in families with in-
herited tumor syndromes, including retinoblastoma
(Sippel et al. 1998), type 1 (Lazaro et al. 1994) and type
2 neurofibromatosis (Evans et al. 1998; Kluwe and
Mautner 1998), and the two known tuberous-sclerosis
genes, TSC1 (Kwiatkowska et al. 1999) and TSC2 (Yates
et al. 1997). Since the gene for VHL is now known (Latif
et al. 1993) and since VHL-gene mutations have been
detected in leukocyte DNA in 100%of germline-affected
individuals (Stolle et al. 1998), it may be possible to
detect cases of VHL mosaicism and to screen for pre-
symptomatic disease in at-risk individuals.
An individual mosaic for a mutation may be asymp-
tomatic or may present with various manifestations of
the disease. Although a mosaic parent tends to have less
severe disease than does his or her offspring, this may
not always be the case (Zlotogora 1998). In our two
cases this appears to be true for family 1, in which the
mosaic parent had subclinical disease found only after
screening by radiographic evaluation. In the other case
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Table 2
Mutation Analysis (From Lymphocytes) of Parents with VHL Mosaicism and Affected Offspring
FAMILY 1 FAMILY 2
Index Case Mosaic Parent Index Case Mosaic Parent
Southern blot Positive NDM NDM NDM
Direct sequencing NDM in remaining normal allele NDM delTTC nt 439–441 1:13 clones delTTC nt 439–441
FISH Deletion detected 47% of cells positive
for allele deletion NA NA
CSGE NA NA NA Gel shift detected
NOTE.—NA = not applicable; NDM = no detectable mutation.
Figure 5 CSGE of samples from family 2. Genomic DNA from
control (lane 1) and patient (lanes 2–5) samples was amplified with
primers for exon 1. PCR products were denatured, reannealed, and
analyzed by CSGE (Ganguly et al. 1993). Genomic DNAwas extracted
from the peripheral blood of a normal control (lane 1), peripheral
blood from IV:6 (lane 2), peripheral blood from III:4 (lane 3), buccal
cells from III:4 (lane 4), cultured skin fibroblasts from III:4 (lane 5).
Arrows indicate position of the shifted bands.
(family 2), the VHL-mosaic parent developed advanced,
symptomatic VHL disease affecting the CNS, kidney,
and pancreas and was diagnosed before genetic analysis
was performed. Difference in degree of disease severity,
if caused by mosaicism, may reflect whether the muta-
tion occurred in the VHL gene early or late in embry-
ogenesis. Differences between family 1 and family 2, in
clinical spectrum of disease expression, may be due to
phenotype-genotype variations known to occur in VHL.
Parental mosaicism may account for some apparently
sporadic or new cases of VHL and has important im-
plications in the genetic counseling of families affected
by VHL. An individual mosaic for a disease mutation
is at increased risk for having affected offspring, despite
testing negative for the mutation by routine DNA di-
agnostic tests. Additional molecular evaluation may be
necessary to confirm the diagnosis of mosaicism. In this
report, the parents with mosaicism from each kindred
were negative for VHL mutations detected in their af-
fected offspring when tested by standard Southern blot
analysis and DNA sequencing of their PBLs. Tissues
bearing the VHL mutation will vary from one case of
mosaicism to another. When possible, additional tissue
should be evaluated for mosaicism (Zlotogora 1998;
Kent-First 1999). We evaluated buccal-cell DNA and
fibroblasts DNA in family 2, individual III:4. For family
1, buccal cell DNA provides insufficient high-molecular-
weight DNA to allow an entire allele deletion to be de-
tected by Southern blot analysis.
Of 181 kindreds affected by VHL that were screened
at the NIH, 42 (23%) included cases with VHL disease
in individuals whose parents and siblings had no history
of the disease at the time of their diagnosis. We have
now shown 2 (4.8%) of the 42 to have parents mosaic
for VHL.
This is similar to the 4% rate of somatic mosaicism
reported in families affected by NF2 (Evans et al. 1998).
When all living parents of affected individuals are tested,
the number of mosaics among cases without a previous
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family history of VHL may be 15%. It is not feasible to
screen all appropriate tissue from apparently normal
parents for evidence of mosaicism. Some apparently nor-
mal individuals may not choose mutation testing, be-
cause of possible economic and psychosocial implica-
tions. Parents who test negative for the VHL germline
mutation in their affected offspring have a finite risk for
VHL disease and may choose clinical screening. Siblings
of the germline-affected offspring of a mosaic may be
tested for the identified VHL-gene mutation.
Depending on the degree of mosaicism and the tissues
affected, individuals with mosaicism are at increased risk
for development of symptoms of the disease. Detecting
individuals with mosaicism and performing appropriate
evaluation for clinical disease may improve their sur-
vival. In addition, other at-risk family members may be
evaluated for the presence of the disease mutation, prior
to onset of symptoms. It is important to investigate the
parents of a patient with an apparent new mutation, for
the presence of mosaicism, to improve genetic counseling
and medical management of these families and indi-
viduals.
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